Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1475 of 2026 entries
View as:

An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)

Phase: N/A Priority: Normal
NCT ID: NCT01384461 Org: User:
Start: 01/31/11 End: 05/31/13 Due: 05/31/14

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01419197 Org: User:
Start: 09/30/11 End: 08/31/15 Due: 08/31/16

A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.

Phase: N/A Priority: Normal
NCT ID: NCT00721266 Org: User:
Start: 06/30/08 End: 06/30/11 Due: 06/30/12

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01702571 Org: User:
Start: 11/27/12 End: 07/31/20 Due: 07/31/21

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Phase: N/A Priority: Normal
NCT ID: NCT00800735 Org: User:
Start: 04/30/09 End: 03/31/12 Due: 03/31/13

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT04432831 Org: User:
Start: 08/05/20 End: 10/11/23 Due: 10/11/24

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Phase: N/A Priority: Normal
NCT ID: NCT04158258 Org: User:
Start: 02/21/20 End: 06/30/26 Due: 06/30/27

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Phase: N/A Priority: Normal
NCT ID: NCT02486718 Org: User:
Start: 10/31/15 End: 08/30/35 Due: 08/30/36

A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia to Describe Medical Resource Utilization and Burden of Illness

Phase: N/A Priority: Normal
NCT ID: NCT01959659 Org: User:
Start: 05/31/13 End: 04/30/14 Due: 04/30/15

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Phase: N/A Priority: Normal
NCT ID: NCT01772472 Org: User:
Start: 04/03/13 End: 05/23/24 Due: 05/23/25

Basmisanil Positron Emission Tomography Study in Japanese Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02534207 Org: User:
Start: 08/31/15 End: 11/30/15 Due: 11/30/16

A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients

Phase: N/A Priority: Normal
NCT ID: NCT00048152 Org: User:
Start: 12/31/00 End: 03/31/06 Due: 03/31/07

A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program

Phase: N/A Priority: Normal
NCT ID: NCT02791269 Org: User:
Start: 01/31/06 End: 07/31/08 Due: 07/31/09

A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.

Phase: N/A Priority: Normal
NCT ID: NCT00461058 Org: User:
Start: 05/31/07 End: 12/31/07 Due: 12/31/08

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Phase: N/A Priority: Normal
NCT ID: NCT03085810 Org: User:
Start: 03/24/17 End: 04/27/23 Due: 04/27/24

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Phase: N/A Priority: Normal
NCT ID: NCT01990248 Org: User:
Start: 03/23/13 End: 07/26/16 Due: 07/26/17

A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease

Phase: N/A Priority: Normal
NCT ID: NCT00002397 Org: User:
Start: - End: - Due: -

A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection

Phase: N/A Priority: Normal
NCT ID: NCT02391805 Org: User:
Start: 05/17/15 End: 10/16/17 Due: 10/16/18

A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

Phase: N/A Priority: Normal
NCT ID: NCT03222310 Org: User:
Start: 07/18/17 End: 09/06/17 Due: 09/06/18

A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00810199 Org: User:
Start: 03/31/09 End: 01/31/13 Due: 01/31/14

A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin

Phase: N/A Priority: Normal
NCT ID: NCT01482377 Org: User:
Start: 12/31/11 End: 02/29/16 Due: 02/28/17

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.

Phase: N/A Priority: Normal
NCT ID: NCT00614471 Org: User:
Start: 08/31/07 End: 10/31/09 Due: 10/31/10

A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01844674 Org: User:
Start: 09/02/13 End: 08/26/14 Due: 08/26/15

A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT00717405 Org: User:
Start: 10/31/08 End: 10/31/14 Due: 10/31/15

A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02595762 Org: User:
Start: 10/30/16 End: 11/30/23 Due: 11/30/24